Hypercalcemia of malignancy (corrected serum calcium 12 mg/dL): 4 mg
(maximum) IV x 1. Wait at least 7 days before considering retreatment.
Renal toxicity: Evidence of renal deterioration defined as an increase of 0.5
mg/dL (pt's with nml baseline Scr) or an increase of 1 mg/dL (pt's with abnormal
baseline Scr) : Evaluate risk versus benefit. Discontinue further dosing until
renal function returns to within 10% of baseline. Reinitiate dose at the same
dose administered prior to treatment interruption. DOSAGE AND ADMINISTRATION
Parenteral drug products should be inspected visually for particulate matter and
discoloration prior to administration, whenever solution and container permit.
Hypercalcemia of Malignancy
The maximum recommended dose of Zometa in hypercalcemia of malignancy
(albumin-corrected serum calcium 12 mg/dL [3.0 mmol/L]) is 4 mg. The 4-mg dose
must be given as a single-dose intravenous infusion over no less than 15
minutes. Patients who receive Zometa should have serum creatinine assessed prior
to each treatment.
Dose adjustments of Zometa are not necessary in treating patients for
hypercalcemia of malignancy presenting with mild-to-moderate renal impairment
prior to initiation of therapy (serum creatinine <400 µmol/L or <4.5 mg/dL).
Patients should be adequately rehydrated prior to administration of Zometa.
Consideration should be given to the severity of, as well as the symptoms of,
tumor-induced hypercalcemia when considering use of Zometa. Vigorous saline
hydration, an integral part of hypercalcemia therapy, should be initiated
promptly and an attempt should be made to restore the urine output to about 2
L/day throughout treatment. Mild or asymptomatic hypercalcemia may be treated
with conservative measures (i.e., saline hydration, with or without loop
diuretics). Patients should be hydrated adequately throughout the treatment, but
overhydration, especially in those patients who have cardiac failure, must be
avoided. Diuretic therapy should not be employed prior to correction of
Retreatment with Zometa 4 mg may be considered if serum calcium does not return
to normal or remain normal after initial treatment. It is recommended that a
minimum of 7 days elapse before retreatment, to allow for full response to the
initial dose. Renal function must be carefully monitored in all patients
receiving Zometa and serum creatinine must be assessed prior to retreatment with
Multiple Myeloma and Metastatic Bone Lesions of Solid Tumors
The recommended dose of Zometa in patients with multiple myeloma and metastatic
bone lesions from solid tumors for patients with creatinine clearance >60 mL/min
is 4 mg infused over no less than 15 minutes every 3-4 weeks. The optimal
duration of therapy is not known.
Upon treatment initiation, the recommended Zometa doses for patients with
reduced renal function (mild and moderate renal impairment) are listed in Table
1. These doses are calculated to achieve the same AUC as that achieved in
patients with creatinine clearance of 75 mL/min. Creatinine clearance (CrCl) is
calculated using the Cockcroft-Gault formula.
Reduced Doses for Patients with Baseline CrCl <60
National Institutes of Health, U.S. National Library of Medicine,
DailyMed Database. Provides access to the latest drug monographs submitted to the
Food and Drug Administration (FDA). Please review the latest applicable package insert for
additional information and possible updates. A local search
option of this data can be found here.
The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a substitute for clinical
judgment. Neither GlobalRPh Inc. nor any other party involved in the
preparation of this program shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material.PLEASE READ THE DISCLAIMER
BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU
AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER. Read